[{"id":"b0a219e9-f08b-4dc8-9baf-aea7746f89fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02287428","created_at":"2021-01-18T10:46:55.814Z","updated_at":"2024-07-02T16:35:00.693Z","phase":"Phase 1","brief_title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","source_id_and_acronym":"NCT02287428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • temozolomide • Neo Vax (NEO-PV-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-27"},{"id":"cbf25b80-812c-4077-9111-bd170e1a9071","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219450","created_at":"2021-01-18T15:53:18.906Z","updated_at":"2024-07-02T16:35:08.018Z","phase":"Phase 1","brief_title":"A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.","source_id_and_acronym":"NCT03219450","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":" | ","alterations":" IGH mutation","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Neo Vax (NEO-PV-01) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-04-23"},{"id":"b8b377f8-f74b-4e8e-8bac-28bf811e0fc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02129075","created_at":"2021-01-18T09:52:16.035Z","updated_at":"2024-07-02T16:36:20.676Z","phase":"Phase 2","brief_title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","source_id_and_acronym":"NCT02129075","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CTAG1B • CD4 • PRAME","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B • CD4 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Mobista (CDX-301) • Neo Vax (NEO-PV-01) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 03/28/2016","primary_completion_date":" 03/28/2016","study_txt":" Completion: 05/18/2018","study_completion_date":" 05/18/2018","last_update_posted":"2021-11-16"},{"id":"8eed0cec-c7e9-4245-8aae-8ccb9526e74e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02897765","created_at":"2021-01-18T14:13:14.197Z","updated_at":"2024-07-02T16:36:34.069Z","phase":"Phase 1","brief_title":"A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer","source_id_and_acronym":"NCT02897765","lead_sponsor":"BioNTech US Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2021-02-25"},{"id":"69b7373d-301a-4a80-927a-95498da24caf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01970358","created_at":"2021-06-22T23:53:11.164Z","updated_at":"2024-07-02T16:36:37.566Z","phase":"Phase 1","brief_title":"A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma","source_id_and_acronym":"NCT01970358","lead_sponsor":"Patrick Ott, MD","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2020-12-09"},{"id":"12cfe499-9e9b-48eb-9c6a-c1e8b9542d7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03166254","created_at":"2021-01-18T15:36:59.212Z","updated_at":"2024-07-02T16:37:00.604Z","phase":"Phase 1","brief_title":"Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT03166254","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2019-04-12"}]